Table 3. Univariate Cox proportional hazards analysis on biochemical recurrence-free survival in the training (n = 410, Probe cg19724470) and validation cohort (n = 259) of prostate cancer patients treated by radical prostatectomy.
Univariate Cox Analysis | ||||
---|---|---|---|---|
Training Cohort | Validation Cohort | |||
Hazard ratio [95% CI] |
p-value | Hazard ratio [95% CI] |
p-value | |
pT category (pT3 & pT4 vs. pT2 & pT1) | 5.37 [2.14-13.5] | <0.001 | 2.70 [1.56-4.69] | <0.001 |
ISUP grading group (1 vs. 2 vs. 3 vs. 4 vs. 5) | 1.69 [1.34-2.13] | <0.001 | 2.00 [1.65-2.44] | <0.001 |
Surgical margin (R1 vs. R0) | 1.49 [0.87-2.56] | 0.15 | 2.31 [1.32-4.06] | 0.003 |
Nodal status (pN1 vs. pN0) | 1.84 [1.00-3.35] | 0.049 | 1.39 [0.55-3.50] | 0.49 |
Preoperative PSA level (continuous) | 1.04 [1.02-1.05] | <0.001 | 1.01 [1.00-1.02] | 0.11 |
AR expression§ (AR positive vs. AR negative) | 0.96 [0.49-1.89] | 0.91 | 0.76 [0.50-1.16] | 0.20 |
ERG# (ERG-positive vs. ERG-negative) | 0.80 [0.40-1.57] | 0.51 | 0.77 [0.40-1.50] | 0.44 |
Age (continuous) | 1.02 [0.98-1.06] | 0.39 | 1.01 [0.97-1.06] | 0.56 |
mPD-L1 (continuous) | 1.02 [1.00-1.03] | 0.024 | 1.24 [1.08-1.43] | 0.002 |
mPD-L1 (optimized cut-off, mPD-L1high vs. mPD-L1low) | 2.60 [1.50-4.51] | 0.001 | 1.90 [1.09-3.31] | 0.023 |